TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction. Banner

Category: testosterone

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →

Read more

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →

Read more

Gender disparity in sexual health options for women: Experts call on pharma and drug regulators to address

  In 2015 Comment in the prestigious medical journal Lancet Diabetes & Endocrinology by two of the world’s leading female sexual health specialists, Prof…. Continue Reading →

Read more

BBC Menopause and testosterone replacement therapy

Over 900 specialist menopause physicians from around the world attended The European Menopause and Andropause Society conference held in Berlin on 15-17th May 2019. Numerous… Continue Reading →

Read more

Effects of testosterone therapy in women – new systematic review and meta-analysis

It has been over a decade since the last systematic review and meta-analysis on the effects of testosterone for women was conducted as an… Continue Reading →

Read more

Hypoactive Sexual Desire Disorder (HSDD) re-defined

In late 2018 the World Health Organisation (WHO) released an update to The International Classification of Disease (ICD). ICD is a system of medical coding created… Continue Reading →

Read more

Axiron® discontinued – Upgrade to AndroForte® 5

Axiron® discontinued – Upgrade to AndroForte® 5   Axiron 2% testosterone solution has been discontinued in Australia effective 4th December 2017 after Lilly terminated its… Continue Reading →

Read more

FDA acknowledges there is a medical need for treating female sexual dysfunction

In late October 2016 the US FDA released draft guidance for Industry on Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment.  This document states ”… Continue Reading →

Read more
Federal Court Proceedings Demonstrate Risk  To Compounding Pharmacies thumbnail
Categories: ,

Federal Court Proceedings Demonstrate Risk To Compounding Pharmacies

MEDIA RELEASE 3rd August 2017   A recent Federal Court case highlights the very real risk and cost to Compounding Pharmacies who do not… Continue Reading →

Read more

EDUCATION: View presentations on testosterone management in men and women

EDUCATION View presentations on testosterone management in men and women In June 2017 the Lawley website added a ‘Health Professional Section’. This password protected learning area will… Continue Reading →

Read more